About Coherex
Coherex is a company based in Salt Lake City (United States) founded in 2003 was acquired by Biosense Webster in November 2015.. Coherex has raised $25.03 million across 2 funding rounds from investors including BioSense Webster, Tullis Health Investors and Signal Peak. The company has 19 employees as of December 31, 2016. Coherex operates in a competitive market with competitors including PECA Labs, Xeltis, Occlutech, Endonovo Therapeutics and AdvancedCPR Solutions, among others.
- Headquarter Salt Lake City, United States
- Employees 19 as on 31 Dec, 2016
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Coherex Medical, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$25.03 M (USD)
in 2 rounds
-
Latest Funding Round
$16.5 M (USD), Series B
Aug 20, 2009
-
Investors
BioSense Webster
& 3 more
-
Employee Count
19
as on Dec 31, 2016
-
Acquired by
Biosense Webster
(Nov 20, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Coherex
Coherex has successfully raised a total of $25.03M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $16.5 million completed in August 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $16.5M
-
First Round
First Round
(18 Apr 2007)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2009 | Amount | Series B - Coherex | Valuation |
investors |
|
| Apr, 2007 | Amount | Series A - Coherex | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Coherex
Coherex has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include BioSense Webster, Tullis Health Investors and Signal Peak. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are made by Tullis Health Investors.
|
Founded Year | Domain | Location | |
|
Early-stage investments in US tech and life sciences are targeted.
|
Founded Year | Domain | Location | |
|
Early stage VC firm investing in the US and Korea
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Coherex
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Coherex
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Coherex Comparisons
Competitors of Coherex
Coherex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PECA Labs, Xeltis, Occlutech, Endonovo Therapeutics and AdvancedCPR Solutions, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pediatric cardiac surgical devices are developed for congenital heart defects.
|
|
| domain | founded_year | HQ Location |
Developer of bioabsorbable synthetic heart valves and vascular grafts
|
|
| domain | founded_year | HQ Location |
Provider of minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart failure
|
|
| domain | founded_year | HQ Location |
Bioelectronic devices are developed for regenerative medicine therapies.
|
|
| domain | founded_year | HQ Location |
CPR products for sudden cardiac arrest treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Coherex
When was Coherex founded?
Coherex was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Where is Coherex located?
Coherex is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Is Coherex a funded company?
Coherex is a funded company, having raised a total of $25.03M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.53M, raised on Apr 18, 2007.
How many employees does Coherex have?
As of Dec 31, 2016, the latest employee count at Coherex is 19.
What does Coherex do?
Medical devices for structural heart disease were developed by Coherex Medical, Inc., founded as Proximare, Inc. in 2003 and renamed in 2006. A patent foramen ovale closure system was created to promote tissue in-growth for sustained closure. Operations focused on cardiovascular implants in the medtech sector. The company, based in Salt Lake City, United States, was acquired by Johnson Johnsons Biosense Webster in November 2015.
Who are the top competitors of Coherex?
Coherex's top competitors include Xeltis, PECA Labs and Endonovo Therapeutics.
Who are Coherex's investors?
Coherex has 4 investors. Key investors include BioSense Webster, Tullis Health Investors, Signal Peak, and Oxford Bioscience Partners.